IRD
Opus Genetics, Inc. (IRD) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (D). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.7) | C- (1.9) | D (1.3) | B (3.2) | C+ (2.6) | C (2.3) |
| 2026-11-05 | C+ (2.8) | D+ (1.6) | C- (2.0) | B (3.2) | C+ (2.7) | C (2.4) |
| 2026-10-29 | C+ (2.8) | D+ (1.5) | C- (2.1) | B- (3.1) | C+ (2.7) | C (2.5) |
| 2026-10-22 | C+ (2.8) | D+ (1.5) | C- (2.1) | B+ (3.7) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | C+ (2.8) | D+ (1.6) | C- (2.1) | B+ (3.6) | C+ (2.6) | C+ (2.5) |